US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SIMPLIFY MANAGED FUTURES STRATEGY ETF

27.49

-0.5635-2.01%

Volume:100.77K

Turnover:2.79M

Market Cap:- -

PE:- -

High:27.99

Open:27.92

Low:27.36

Close:28.05

Loading ...

Overview Company News Filings

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

WEEX spot trading is now live with PUMP, TAC, LUCKYMOON, C, and VELVET.

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

ProQR Submits CTA for Phase 1 Study of AX-0810

Animoca Brands has announced the purchase of CTA tokens from the open market

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

Press Release: Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Financial Services Firms Deepen Client Engagement with ON24-powered Digital Experiences

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

ACCESS Newswire

Press Release: Gentex Announces Closing of VOXX International Acquisition

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

ACCESS Newswire

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

Press Release: CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CTA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","market":"US","secType":"STK","nameCN":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","latestPrice":27.4865,"timestamp":1753978246630,"preClose":28.05,"halted":0,"volume":100766,"delay":0,"floatShares":40300001,"shares":0,"eps":0,"marketStatus":"Trading","change":-0.5635,"latestTime":"07-31 12:10:56 EDT","open":27.92,"high":27.99,"low":27.36,"amount":2792136.379792,"amplitude":0.02246,"askPrice":27.58,"askSize":300,"bidPrice":27.39,"bidSize":300,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1753992000000},"marketStatusCode":2,"adr":0,"exchange":"AMEX","adjPreClose":28.05,"sharesOutstanding":40300001,"nav":28.31,"aum":1140902212.95,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":28.05,"preClose":28.05,"latestTime":"08:02 EDT","volume":3,"amount":84.15,"timestamp":1753963347271},"postHourTrading":{"tag":"盘后","latestPrice":28.05,"preClose":28.05,"latestTime":"16:10 EDT","volume":11,"amount":308.55,"timestamp":1753906204366},"volumeRatio":0.703025,"impliedVol":0.1489,"impliedVolPercentile":0.5812},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","floatShares":40300001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.703025,"shares":0,"dividePrice":0,"high":27.99,"amplitude":0.02246,"preClose":28.05,"low":27.36,"week52Low":25.6601,"pbRate":"--","week52High":30.213,"institutionHeld":0,"latestPrice":27.4865,"eps":0,"divideRate":0,"volume":100766,"delay":0,"ttmEps":0,"open":27.92,"prevYearClose":27.89,"prevWeekClose":28.08,"prevMonthClose":26.74,"prevQuarterClose":26.74,"fiveDayClose":28.29,"twentyDayClose":27.03,"sixtyDayClose":27.37},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555008794","title":"Pharming Group reports second quarter and first half 2025 financial results and provides business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2555008794","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555008794?lang=en_us&edition=fundamental","pubTime":"2025-07-31 13:00","pubTimestamp":1753938000,"startTime":"0","endTime":"0","summary":"Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST and Joenja revenue growthRUCONEST second quarter revenue increase","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/31/3124636/0/en/Pharming-Group-reports-second-quarter-and-first-half-2025-financial-results-and-provides-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA","BK4215","BK4566","BK4585","EEA","ODD","BK4183","MAA","CHMP","BK4139","BK4588","IE00BFMHRM44.USD","NICE","EMA","BK4081","BK4087","BK4543","PHAR","BK4023","IE0009354923.USD"],"gpt_icon":0},{"id":"2553042210","title":"Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2553042210","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553042210?lang=en_us&edition=fundamental","pubTime":"2025-07-23 20:00","pubTimestamp":1753272000,"startTime":"0","endTime":"0","summary":"- SGT-501 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations - - Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to ad","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/23/3120186/0/en/Solid-Biosciences-Receives-FDA-Fast-Track-Designation-for-SGT-501-First-in-Class-Gene-Therapy-for-Catecholaminergic-Polymorphic-Ventricular-Tachycardia-CPVT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","CTA","SLDB","BK4588","IE00BFXG0V08.USD","BK4585","IE00BYQQ9H92.USD","FA","IE00B5TLWC47.USD","FAST","BK4567","BK4539","BK4139","BK4130","BK4535"],"gpt_icon":0},{"id":"2551141101","title":"WEEX spot trading is now live with PUMP, TAC, LUCKYMOON, C, and VELVET.","url":"https://stock-news.laohu8.com/highlight/detail?id=2551141101","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551141101?lang=en_us&edition=fundamental","pubTime":"2025-07-16 11:35","pubTimestamp":1752636900,"startTime":"0","endTime":"0","summary":"BlockBeats News, July 16, WEEX announced that it will list Cross The Ages (CTA) and Exim Token (EXIM) spot trading today at 17:00 (UTC+8). Additionally, WEEX has recently listed pump.fun (PUMP), TAC Protocol (TAC), Lucky Moon (LUCKYMOON), Chainbase (C), and Velvet (VELVET) for spot trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/302987","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["LU0106831901.USD","LU0128525689.USD","LU0477156953.USD","BK4534","LU0130102774.USD","LU1791807156.HKD","BK4588","BK4585","LU1366192091.USD","LU0130517989.USD","LU0162691827.USD","LU2462157665.USD","LU1201861249.SGD","TAC","BK4207","IE00BSNM7G36.USD","LU0170899867.USD","LU0098860793.USD","BK4559","LU0310800965.SGD","PUMP","LU0072461881.USD","LU0980610538.SGD","LU2360032135.SGD","BK4105","BK4504","CTA","BK4566","BK4179","LU0648001328.SGD","LU1668664300.SGD","LU2417539215.USD","LU0052756011.USD","LU1162221912.USD","LU1267930227.SGD","LU2125154778.USD","LU2236285917.USD","LU0320765646.SGD","LU2125154935.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2551931189","title":"Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in  Familial Adenomatous Polyposis (FAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2551931189","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551931189?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:30","pubTimestamp":1752496200,"startTime":"0","endTime":"0","summary":"July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in  Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/14/3114750/0/en/Biodexa-Announces-Filing-of-CTA-in-Europe-for-Phase-3-Serenta-Trial-in-Familial-Adenomatous-Polyposis-FAP.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EMA","BDRX","CTA","BK4081"],"gpt_icon":0},{"id":"2550637201","title":"Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2550637201","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550637201?lang=en_us&edition=fundamental","pubTime":"2025-07-09 20:35","pubTimestamp":1752064500,"startTime":"0","endTime":"0","summary":"Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/09/3112575/0/en/Moleculin-Expands-Phase-3-MIRACLE-Clinical-Trial-into-the-Country-of-Georgia-Enrollment-Update-and-Future-Plans.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA","BK4156","BK4081","EMA"],"gpt_icon":0},{"id":"2550557823","title":"Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2550557823","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550557823?lang=en_us&edition=fundamental","pubTime":"2025-07-09 04:05","pubTimestamp":1752005100,"startTime":"0","endTime":"0","summary":"- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Desi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/08/3112195/0/en/Solid-Biosciences-Announces-FDA-IND-and-Health-Canada-CTA-Approval-for-First-in-Class-Cardiac-Gene-Therapy-to-Treat-Catecholaminergic-Polymorphic-Ventricular-Tachycardia-CPVT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SLDB","BK4130","BK4139","FA","CTA","BK4535"],"gpt_icon":0},{"id":"2546751484","title":"ProQR Submits CTA for Phase 1 Study of AX-0810","url":"https://stock-news.laohu8.com/highlight/detail?id=2546751484","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546751484?lang=en_us&edition=fundamental","pubTime":"2025-06-27 05:01","pubTimestamp":1750971684,"startTime":"0","endTime":"0","summary":"ProQR ( ($PRQR) ) just unveiled an update. On June 26, 2025, ProQR Therapeutics announced the submission of a Clinical Trial Application (CTA) to t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/proqr-submits-cta-for-phase-1-study-of-ax-0810?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/proqr-submits-cta-for-phase-1-study-of-ax-0810?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AX","LU2360107671.USD","LU1861217088.USD","LU1861220207.SGD","BK4195","BK4211","CTA"],"gpt_icon":0},{"id":"2545109460","title":"Animoca Brands has announced the purchase of CTA tokens from the open market","url":"https://stock-news.laohu8.com/highlight/detail?id=2545109460","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545109460?lang=en_us&edition=fundamental","pubTime":"2025-06-21 09:22","pubTimestamp":1750468920,"startTime":"0","endTime":"0","summary":"BlockBeats News, June 21st, According to official sources, Animoca Brands has announced a strategic partnership with the blockchain cross-media ecosystem Cross the Ages. Animoca Brands will support Cross the Ages' upcoming multiplayer action role-playing game, Arise, which is set to be officially launched soon. The company has already begun purchasing CTA tokens from the open market . Additionally, Animoca Brands will provide advice to the project on marketing strategy, audits, and tokenomics.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/299353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["CTA"],"gpt_icon":0},{"id":"2540719842","title":"Why AbCellera Biologics Stock Raced Nearly 6% Higher Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2540719842","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540719842?lang=en_us&edition=fundamental","pubTime":"2025-06-03 06:45","pubTimestamp":1748904300,"startTime":"0","endTime":"0","summary":"The company had some encouraging regulatory news to report.It concerned a dermatitis drug the biotech is currently developing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/02/why-abcellera-biologics-stock-raced-nearly-6-highe/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4121","BK4535","ABCL","CTA"],"gpt_icon":0},{"id":"2536812996","title":"Press Release: Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2536812996","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536812996?lang=en_us&edition=fundamental","pubTime":"2025-05-19 20:31","pubTimestamp":1747657860,"startTime":"0","endTime":"0","summary":"-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology --. -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --. -- Implementing cost cutting measures to significantly reduce cash needs in advance of key data inflection points --. \"The first-in-human data for PM359 announced today represent a landmark moment for the industry and for our company, demonstrating the unequivocal power of Prime Editing to change patients' lives, with a single dose of PM359 providing potentially curative benefit in a matter of weeks,\" said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. \"These data also reinforce the critical importance of ensuring Prime Medicine is positioned to withstand the challenges of the current environment, so that we can one day deliver the tremendou","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","CTA","BK4099","03160","CEO","BK4022","CFO","BK4555","R","BK4604","BK4585","TM","BK4232","PRME"],"gpt_icon":0},{"id":"2535042243","title":"Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535042243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535042243?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220400,"startTime":"0","endTime":"0","summary":"Clinical Trials of Budoprutug in Primary Membranous Nephropathy , Immune Thrombocytopenia , and Systemic Lupus Erythematosus  on Track to Initiate in 2025. CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025. Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer. Strong Financial Position, with Cash Runway Expected Through 2027. \"2025 is a critical year of execution for Climb Bio and we continue to make excellent progress developing a differentiated pipeline targeting immune-mediated diseases with expansive therapeutic and commercial potential,\" said Aoife Brennan, President and CEO of Climb Bio. \"Our most advanced program, budoprutug, a potential best-in-class anti-CD19 monoclonal antibody designed to treat B-cell mediated diseases, remains on track to initiate clinical studies in ITP and SLE in the coming weeks and in pMN in the second half of 2025. We plan to provide clarity on the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SLE","BK4139","CLYM","ITP","BK4077","CTA","BK4199"],"gpt_icon":0},{"id":"2531942392","title":"Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531942392","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531942392?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:30","pubTimestamp":1745872200,"startTime":"0","endTime":"0","summary":"BURLINGTON, Mass., April 28, 2025  -- Fractyl Health, Inc.  , a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes , today announced that it will deliver an oral presentation of compelling preclinical data from its Rejuva single-administration Smart GLP-1 pancreatic gene therapy platform at the American Society of Gene and Cell Therapy  2025 Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana.Title: Endoscopic Ultrasound-Guided Delivery of Human Glucagon-like Peptide-1 Pancreatic Gene Therapy: Safety and Feasibility in a Porcine ModelSession: AAV Preclinical and Proof-of-Concept StudiesDate and Time: Saturday, May 17, 2025, 9:15 a.m. – 9:30 a.m. CTLocation: NOLA Theater A. Investor Contact Brian Luque, Head of Investor Relations and Corporate DevelopmentIR@fractyl.com, 951.206.1200","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fractyl-health-present-compelling-preclinical-203000689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","GUTS","CTA","GLP","BK4082","BK4107","BK4590","BK4144","BK4117"],"gpt_icon":0},{"id":"2530402730","title":"Financial Services Firms Deepen Client Engagement with ON24-powered Digital Experiences","url":"https://stock-news.laohu8.com/highlight/detail?id=2530402730","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530402730?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"New research reveals how digital-first strategies are driving stronger relationships and propelling business outcomes. SAN FRANCISCO, April 28, 2025----ON24 , a leading intelligent engagement platform for B2B sales and marketing, today released its 2025 Financial Services Digital Engagement Benchmarks Report, highlighting how financial services and asset management firms are transforming client education through digital engagement. The findings show a surge in interactive, data-driven experiences, with firms leveraging first-party engagement from webinars, virtual events, and content hubs to foster deeper relationships, enhance awareness and drive pipeline growth.\"The finance industry isn’t just going digital – it's racing towards hyper-personalization,\" said Mark Bornstein, VP of Marketing, ON24. \"Our research shows that firms that combine scalability with personalization see stronger engagement, more meaningful client interactions and ultimately, better business outcomes. The ON24 pl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/financial-services-firms-deepen-client-120000695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONTF","CTA","BK4023"],"gpt_icon":0},{"id":"2527629431","title":"Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2527629431","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527629431?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:00","pubTimestamp":1744801200,"startTime":"0","endTime":"0","summary":"Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025. CLN-978 is also being studied in the U.S., Europe, and Australia for systemic lupus erythematosus. About CLN-978CLN-978 is a novel, differentiated and highly potent CD19xCD3 bispecific T cell engager. CLN-978 triggers redirected lysis of CD19-expressing target cellsin vitroandin vivo. CLN-978 is engineered to achieve very high affinity binding to CD19 to efficiently target B cells, including those with very low CD19 levels. Small in molecular size , CLN-978 contains two single-chain variable fragments, one b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cullinan-therapeutics-receives-approval-european-110000424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACR","BK4110","BK4139","CTA","MDCO","CGEM"],"gpt_icon":0},{"id":"2526923550","title":"CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2526923550","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526923550?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:30","pubTimestamp":1744284600,"startTime":"0","endTime":"0","summary":"Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation. Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first data readout anticipated in H2 2025. Filed IND and CTA submissions for Phase 1 study with proprietary off-the-shelf program in squamous non-small cell lung cancer . Received FDA clearance to proceed with sqNSCLC Phase 1 study; expected tostart in H2 2025. Invoiced 10 million milestone payment following initiation of Phase 1 of the combined Phase 1/2 study of a seasonal influenza/COVID-19 combination vaccine; program fully licensed to GSK. Received positive validity decision for patent EP 3 708 668 B1 in amended form from European Patent Office  in inter partes proceedings against BioNTech SE. Cash and cash equivalents position of 481.7 million as of December 31, 2024; reaffirming expected cash runway into 2028. TBINGEN, GERMANY AND BOSTON, MA / ACCESS ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/curevac-announces-financial-results-fourth-113000748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","BK4139","BNTX","BK4548","BK4535","CVAC","SITC","BK4080","BK4231","CTA","BK4551","BK4585","BK4588"],"gpt_icon":0},{"id":"2524111983","title":"Press Release: Gentex Announces Closing of VOXX International Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2524111983","media":"Dow Jones","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524111983?lang=en_us&edition=fundamental","pubTime":"2025-04-01 21:00","pubTimestamp":1743512400,"startTime":"0","endTime":"0","summary":"ZEELAND, Mich., April 01, 2025  -- Gentex Corporation  announced today that it has closed on the strategic acquisition of VOXX International, a global supplier of automotive and consumer electronics as well as premium audio equipment.Gentex is a technology company and long-time supplier of electro-optical products for the global automotive, aerospace, fire protection and medical industries. The company is best known for automotive electronics, but continues to grow its capabilities in vision systems, sensing, AI development, biometrics, home automation, and other smart technologies.Under the terms of the agreement, which was recently approved by VOXX shareholders, Gentex acquired all the issued and outstanding shares of VOXX common stock not already owned by Gentex for a purchase price of $7.50 per share. The Company expects its annual revenue to increase in the range of $325 million to $375 million as a result of the acquisition.\"We want to continue the legacy of VOXX Founder John Sha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4124","R","VOXX","BK4232","BK4022","IE00BD6J9T35.USD","BK4078","CTA","GNTX"],"gpt_icon":0},{"id":"2523947806","title":"CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2523947806","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523947806?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:15","pubTimestamp":1743423300,"startTime":"0","endTime":"0","summary":"BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. , , a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the fourth quarter ended December 31, 2024, and provided an update on key highlights for 2024.Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, \"2024 was a transformative year for CASI as we strategically pivoted our company toward the development of CID-103 for organ transplant rejection and autoimmune disease. CID-103 is an anti-CD38 antibody with the potential to be a best-in-class treatment for a myriad of autoimmune diseases as well as antibody mediated rejection . We are encouraged by our clinical progress, achieving a milestone with the first Immune Thrombocytopenia  patient dosed in January 2025. Simultaneously, we are diligently working towards resolution of the FDA renal allograft ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/casi-pharmaceuticals-announces-fourth-quarter-121500480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ITP","BK4585","BK4588","BK4199","CASI","BK4006","AMR","CDE","CTA","BK4139","BK4017"],"gpt_icon":0},{"id":"2523917675","title":"Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917675","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917675?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical mu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052163/36461/en/Voyager-Presents-Robust-Preclinical-Data-from-Tau-Targeting-Gene-Therapy-and-Antibody-Programs-at-AD-PD-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","BK4023","CTA","PD","PET","BK4192","LU1169589451.USD"],"gpt_icon":0},{"id":"2522539191","title":"Press Release: CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539191","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539191?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"-- Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders  ongoing, with dosing completed in two of four multiple ascending dose  cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in Q4 2025. -- Nomination of development candidate CMP-SYNGAP-01 to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025. Mr. Mandel-Brehm continued, \"We are also pleased to announce the selection of a development candidate, CMP-SYNGAP-01, for our SYNGAP1-related disorders program based on compelling data across our preclinical studies, including recent non-human primate studies. The discovery and selection of a novel regRNA-targeting antisense oligonucleotide  that increases SYNGAP1 protein levels underscores the transformative potential of our platform to identify and advance this novel class of therapeutic candidates for SYNGAP1-related disorders, a group of neurodevelopmental conditions with no approved therapies that we believe impacts app","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4023","CTA","BK4585","LU1169590202.USD","PD","BK4099","03160","BK4588","BK4604","BK4561","TM","ASO","LU1169589451.USD","CAMP","BK4200","BK4020","BK4555"],"gpt_icon":0},{"id":"2522580965","title":"Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522580965","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522580965?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:01","pubTimestamp":1742986860,"startTime":"0","endTime":"0","summary":"- Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 -. - Commenced Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, the first gene editing technology studied for Hepatitis B, in fourth quarter of 2024 -. - Demonstrated PGENE-HBV was safe and well tolerated with substantial antiviral activity measured by reduction of Hepatitis B surface antigen after only one administration at lowest dose level; Subsequent doses of PBGENE-HBV to follow with data expected throughout 2025 -. \"In 2025, our steadfast focus remains on continued clinical execution as we work to deliver on the promise of our ARCUS gene editing technology through robust clinical data,\" continued Mr. Amoroso. \"The recent reported clinical experience for PBGENE-HBV focused on viral editing and elimination of replicating cccDNA and integrated HBV DNA in Hepatitis B, an extremely large patient population, adds to the com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/precision-biosciences-reports-fourth-quarter-110100032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GHS","CTA","BK4139","DTIL"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTA\",params:#limit:5,,,undefined,":[{"date":"2025-06-25","symbol":"CTA","amount":0.25,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-30","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-06-30"},{"date":"2025-03-26","symbol":"CTA","amount":0.12,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-31"},{"date":"2024-12-23","symbol":"CTA","amount":0.73816,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-31"},{"date":"2024-09-25","symbol":"CTA","amount":0.3,"announcedDate":"2024-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-25","defaultRemindTime":1727271000000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-30","payableDate":"2024-09-25","currency":"USD","dateTimestamp":1727236800000,"payDate":"2024-09-30"},{"date":"2024-06-25","symbol":"CTA","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-06-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTA\",market:\"US\",,,undefined,":[{"executeDate":"2022-08-26","recordDate":"2022-08-29","paymentDate":"2022-08-31","value":0.15,"currency":"USD"},{"executeDate":"2022-09-27","recordDate":"2022-09-28","paymentDate":"2022-09-30","value":0.15,"currency":"USD"},{"executeDate":"2022-10-26","recordDate":"2022-10-27","paymentDate":"2022-10-31","value":0.15,"currency":"USD"},{"executeDate":"2022-11-25","recordDate":"2022-11-28","paymentDate":"2022-11-30","value":0.15,"currency":"USD"},{"executeDate":"2022-12-27","recordDate":"2022-12-28","paymentDate":"2022-12-30","value":1.11096,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTA\",market:\"US\",delay:false,,,undefined,":{}}}